The clinical study, conducted in China, involved 60 patients with non-small cell lung cancer (NSCLC) who were randomised to receive either chemotherapy (cisplatin and paclitaxel) combined with hyperthermia which has been delivered using the BSD-2000 Hyperthermia System or chemotherapy without hyperthermia.

In the study, the researchers compared the short-term tumor regression rate, side effects and quality of life improvement between the two groups. Efficacy was based on World Health Organisation standards and included those patients who had a complete response or a partial response.

BSD said that the percentage of patients who had a CR plus PR and an improved quality of life after three cycles of treatment was increased by the addition of hyperthermia which is 63.33% and 76.67%, respectively, for patients treated with hyperthermia and chemotherapy vs. 36.67% and 40.00% for those treated with chemotherapy alone, p<0.05.

The researchers concluded that ‘BSD2000 deep hyperthermia combined with chemotherapy in patients with NSCLC can increase the efficacy, response rate and quality of life improvement and without increasing side effects compared to chemotherapy alone.’

With the assistance of Dalian Orientech, a privately owned company and its exclusive Chinese distributor, BSD obtained Chinese regulatory (SFDA) approval for the BSD-2000 in 2005, allowing Dalian Orientech to market and sell the system to hospitals throughout China. BSD has placed 17 BSD-2000 systems with Dalian Orientech customers in China.